Table 1.
Population characteristics (n = 176)
| Clinical features | Median | IQR | |
|---|---|---|---|
| Age (years) | 73 | 69–87 | |
| iPSA (ng/mL) | 7.9 | 5.28–12.00 | |
| PSA at PET scan (ng/mL) | 0.62 | 0.43–1.00 | |
| PSAdt at PET scan (months) | 9.8 | 4.7–18.35 | |
| PSAvel at PET scan (ng/mL/year) | 0.5 | 0.2–1.1 | |
| Clinical features | Frequency % (n) | ||
| ISUP grade | 1 | 14.8% (26) | |
| 2 | 25.6% (45) | ||
| 3 | 27.8% (49) | ||
| 4 | 15.3% (27) | ||
| 5 | 11.9% (21) | ||
| Missing | 4.5% (8) | ||
| pT stage | < 3a | 51.1% (90) | |
| ≥ 3a | 44.9% (79) | ||
| Missing | 4.0% (7) | ||
| pN stage | N1 | 6.3% (11) | |
| R (margin) | R1 | 38.6% (68) | |
| Time to PSA relapse from primary therapy (months) | < 12 | 25.0% (44) | |
| ≥ 12 | 75.0% (132) | ||
| Primary therapy | RP ± LND ± adjuvant RT | 96.0% (169) | |
| Primary RT | 3.9% (7) | ||
| Clinical setting of PSA failure | First BCR (subgroup 1) | 43.2% (76) | |
| PSA relapse after SRT in prostate bed (subgroup 2) | 43.2% (76) | ||
| BCP after RP (subgroup 3) | 13.6% (24) | ||